{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade&page=11", "query": { "condition": "High Grade", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 165, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade&page=10&page_size=10" }, "source": "local", "last_synced_at": "2026-10-19T12:13:29.177Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07815704", "title": "Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancers", "High Grade Serous Adenocarcinoma of Ovary", "Ovarian Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Standard of Care (SOC)", "type": "DRUG" }, { "name": "Standard of Care + atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "FEMALE", "summary": "18 Years to 89 Years · Female only" }, "enrollment_count": 40, "start_date": "2026-09", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-16T17:09:24.427Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07815704" }, { "nct_id": "NCT07753824", "title": "A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendiceal Adenocarcinoma", "High Grade Metastatic", "Intraperitoneal", "Ivonescimab", "Paclitaxel", "Phase II" ], "interventions": [ { "name": "IP PTX", "type": "DRUG" }, { "name": "Ivonescimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2027-01-16", "completion_date": "2032-11-28", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-07T00:40:18.055Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07753824" }, { "nct_id": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "High Grade B-Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 20, "start_date": "2026-12-08", "completion_date": "2031-10-08", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-27T04:31:37.232Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07714421" }, { "nct_id": "NCT03984448", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Double-Expressor Lymphoma", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 363, "start_date": "2019-10-22", "completion_date": "2028-08-13", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T12:13:29.177Z", "location_count": 634, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984448" }, { "nct_id": "NCT03587311", "title": "Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Anetumab Ravtansine", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2018-10-12", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T01:19:16.525Z", "location_count": 22, "location_summary": "Orange, California • Aurora, Colorado • Coral Gables, Florida + 19 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587311" }, { "nct_id": "NCT02659241", "title": "Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Carcinomatosis", "Fallopian Tube High Grade Serous Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Stage III Fallopian Tube Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 38, "start_date": "2016-02-04", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-14T22:37:29.774Z", "location_count": 8, "location_summary": "Portland, Oregon • Conroe, Texas • Houston, Texas + 2 more", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02659241" }, { "nct_id": "NCT05465954", "title": "Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Astrocytic Tumor", "Recurrent Glioblastoma, IDH-Wildtype", "Recurrent Gliosarcoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Efineptakin alfa", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2023-01-24", "completion_date": "2031-09-02", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-16T20:19:09.962Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05465954" }, { "nct_id": "NCT04314401", "title": "National Cancer Institute \"Cancer Moonshot Biobank\"", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Esophageal Carcinoma", "Fallopian Tube Carcinoma", "Gastric Carcinoma", "Hormone Receptor-Positive Breast Carcinoma", "Invasive Breast Carcinoma", "Lung Non-Small Cell Carcinoma", "Lung Small Cell Carcinoma", "Malignant Solid Neoplasm", "Melanoma", "Metastatic Prostate Carcinoma", "Multiple Myeloma", "Ovarian Carcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Paracentesis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 1600, "start_date": "2020-11-11", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-17T10:45:27.257Z", "location_count": 147, "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04314401" }, { "nct_id": "NCT04231877", "title": "Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ALK-Positive Large B-Cell Lymphoma", "Aggressive Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Gray-Zone Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Primary Mediastinal Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Glofitamab", "type": "BIOLOGICAL" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2020-10-27", "completion_date": "2031-12-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-17T05:19:53.450Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04231877" }, { "nct_id": "NCT02153580", "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "B-Cell Prolymphocytic Leukemia", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Post-Transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Hairy Cell Leukemia", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-09-24", "completion_date": "2027-08-11", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-16T01:12:16.549Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02153580" } ] }